Omicron Variant Escapes Therapeutic Monoclonal Antibodies (mAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC)

Clin Infect Dis. 2022 Aug 24;75(1):e534-e535. doi: 10.1093/cid/ciac143.

Authors

Céline Boschi^{1

2}, Philippe Colson^{1

2}, Audrey Bancod^{1

2}, Valérie Moal^{1

3}, Bernard La Scola^{1

2}

Affiliations

¹ Microbes, Evolution, Phylogeny et Infection (MEPHI), Aix Marseille Université, Marseille, France.
² Institut Hospitalo-Universitaire Méditerranée-Infection, Marseille, France.
³ Department of Nephrology, Conception hospital, AP-HM, Marseille, France.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal* / therapeutic use
Antibodies, Neutralizing
Antibodies, Viral
Antineoplastic Agents, Immunological*
Humans

Substances

Antibodies, Monoclonal
Antibodies, Neutralizing
Antibodies, Viral
Antineoplastic Agents, Immunological